Latest Breaking News On - ஏரி ப்ளூ மூலதனம் - Page 3 : comparemela.com

Temasek, Lake Bleu lead $156m Series C round for Chinese vaccine developer RecBio

Temasek, Lake Bleu lead $156m Series C round for Chinese vaccine developer RecBio Photo by Diana Polekhina on Unsplash June 14, 2021 Rec-Biotechnology (RecBio), a Chinese developer of genetically engineered vaccines, has secured about 1 billion yuan ($156.3 million) in a Series C round of financing jointly led by Singapore state investor Temasek Holdings and Hong Kong-based asset manager Lake Bleu Capital. Chinese asset management company E Fund Management and private equity firm Boyu Capital participated in the round, alongside existing shareholders such as Legend Capital, an investment unit of China’s Legend Holdings, healthcare fund LYFE Capital, and Sequoia Capital China. The new financing came about seven months after it raked in over 1.5 billion yuan in a Series B round in November 2020. Its Series A round, which was closed in January 2019, collected 500 million yuan from investors including Chinese venture capital firm Oriental Fortune Capital, and CR Capital Management

Abzymo biosciencesChina legend holdingsE fund managementTemasek holdingsHong kong basedLake bleuBoyu capitalLegend capitalLegend holdingsSequoia capitalOriental fortune capitalTaizhou cityJiangsu provinceJiangsu rec biotechnologyBeijing abzymoLake bleu capital

China Digest: WeMed nets over $46m; Tencent, Sequoia back WakeData

China Digest: WeMed nets over $46m; Tencent, Sequoia back WakeData Markus Spiske/Unsplash WeMed nets over $46m in Series D Interventional diagnosis medical equipment provider Beijing WeMed Medical Equipment Co Ltd has received over 300 million yuan ($46 million) in a Series D round led by Lake Bleu Capital, a Hong Kong-based asset management firm. Everest VC and Suzhou Longmen Ventures were the new investors in the round that also saw participation from return backer Lucion. Haoyue Capital served as the exclusive financial advisor, it said in a WeChat post on Thursday. WeMed will deploy the fresh proceeds towards branding, surgical robots, and digital platform initiatives. WeMed’s investors include Huagai Capital, Northern Light Venture Capital and Marathon Venture Partners. Earlier, WeMed had completed a 100-million yuan ($15 million) Series C+ round exclusively from Hillhouse Capital’s GL Ventures.

Wemed medical equipment co ltdRf groupBeijing wemed medical equipmentBeijing wemed medical equipment co ltdLake bleu capitalHong kong basedSuzhou longmen venturesHaoyue capitalHuagai capitalNorthern light venture capitalMarathon ventureHillhouse capitalSequoia capital chinaRedpoint china venturesCountry gardenRedpoint china

GIC-backed Chinese biotech firm Brii Biosciences files for HK IPO

GIC-backed Chinese biotech firm Brii Biosciences files for HK IPO
dealstreetasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dealstreetasia.com Daily Mail and Mail on Sunday newspapers.

Hong kongNorth carolinaUnited statesBrii bioNeil nanpeng shenAlibaba jackMorgan stanleyChina enterprisesHong kong stock exchangeInvesco developing markets fundArch venture fundBrii biosciencesBrii biosciences limitedHong kong stockLake bleu capitalBoyu capital

AffaMed Therapeutics Announces Completion of over US$170 Million Series B Financing Led by Lake Bleu Capital to Further Development of Ophthalmic and Neuroscience Pipeline

AffaMed Therapeutics Announces Completion of over US$170 Million Series B Financing Led by Lake Bleu Capital to Further Development of Ophthalmic and Neuroscience Pipeline
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

Hong kongDayao zhaoWei fuAsia pacificMerck research laboratoriesMount sinai school of medicineGlobal head of business development at beigeneMerck coJanssen pharmaceutical companies of johnsonShanghai medical universityJapan fundBusiness developmentAmed therapeuticsLake bleu capitalPartners investmentSuperstring capital

Durham drug startup to target variety of therapies with $155M in new funding

Durham drug startup to target variety of therapies with $155M in new funding
wraltechwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wraltechwire.com Daily Mail and Mail on Sunday newspapers.

North carolinaUnited statesZhi hongBrii bioBrii biosciencesClay thorpJames kleinTriangle pharmaceuticalsGilead sciencesInvesco developing markets fundNational institute of allergyUs national institutes of healthInvesco developing marketsLake bleu capitalHatteras venture partnersDurham based triangle pharmaceuticals